Analysis Immunoassay of Bevacizumab (BEV) and Cetuximab (CET) by KinExA (CAT#: STEM-MB-0079-CJ)

Introduction

BEV and CET are monoclonal antibodies used for immunotherapy of cancers. And the antigens of BEV and CET in human body are human vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) respectively. Bevacizumab can be used in the treatment of colorectal cancer, but there are certain side effects, such as thrombosis, arterial hypertension, albuminuria, gastrointestinal or nasal septum perforation, abnormal wound healing, irreversible leucoencephalopathy syndrome, allergic rash, and hypersensitivity.Cetuximab injection can be used in combination with radiotherapy for advanced squamous cell carcinoma of the head and neck (SCCHN) , or in combination with platinum-based cancer drugs for fluorouracil for SCCHNS that have recurred (relapsed) or have spread to other parts of the body (metastases). Cetuximab injection is also used with encorafenib in the treatment of metastatic colorectal cancer (CRC, colon and rectal cancer that has spread) and has the BRAF V600E mutation.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

KinExA is a two-stage analysis system. In the first stage, a number of solutions are prepared, where one partner remains constant (constant binding partner, or CBP) and the other (titrant) is variable, usually serially diluted. As the titrant is added, the free CBP decreases and is analysed by a sophisticated and precise microfluorescence measurement device. The signal generated can be mathematically related to the affinity (KD) of the two molecules for each other, as well as the kinetic parameters of binding (kon) and dissociation (koff).

Applications

Oncology & Cancer; Immunology/Inflammation; Pharmacology

Procedure

1. preparation of the functionalized beads which will capture the analyte for measuremen.
2. preparation of a series of solutions consisting of a constant initial concentration of one component of the binary reaction and serial dilutions of the other reactant. The component that is kept constant is the constant binding partner (CBP) , and is the one which will be analyzed.
3. each reaction mixture is sampled and the fluorescence of free CBP bound to the capture beads is obtained for subsequent numerical analysis.

Materials

• Sample Type: Antibodies, Cells, Small Molecules, Proteins, DNA, Lipids, Viruses, Serum, & More
• Equipment: Kinetic Exclusion Assay (KinExA)

Other recommended products

Analysis Immunoassay of GITRL/ hGITR (Human, Mouse) by KinExA (CAT#: STEM-MB-0066-CJ)
Analysis Affinity of Admium-EDTA Complexes Antibodies by KinExA (CAT#: STEM-MB-0038-CJ)
Analysis Affinity of Liver Cancer Antigen Roundabout1 (Robo1) by KinExA (CAT#: STEM-MB-0017-CJ)
Analysis Affinity of Cysteinyl Leukotrienes (CysLTs) by KinExA (CAT#: STEM-MB-0029-CJ)
Analysis Affinity of Met-pep1 to Met by KinExA (CAT#: STEM-MB-0011-CJ)
Analysis Affinity of Monoclonal Antibody (mAb) to Rat DPP-IV Proteins by KinExA (CAT#: STEM-MB-0046-CJ)
Analysis Immunoassay of Cancer Markers ( 2'-deoxycytidine (dCyd) , 8-hydroxy-2'-deoxyguanosine (8HdG) , carbohydrate antigen (CA15-3) , α-fetoprotein (AFP) , and β-subunit of Human Chorionic Gonadotropin (β-HCG) ) by KinExA (CAT#: STEM-MB-0069-CJ)
Analysis Immunoassay of Neonicotinoid Insecticide Thiamethoxam by KinExA (CAT#: STEM-MB-0073-CJ)